In vivo distribution characteristics and anti-tumor effects of doxorubicin encapsulated in PEG-modified niosomes in solid tumor-bearing mice
Authors:
- Tamer ShehataTamer Shehata
- Yusuke KonoYKYusuke Kono
- Kazutaka HigakiKHKazutaka Higaki
- Toshikiro KimuraTKToshikiro Kimura
- Ken-Ichi OgawaraKOKen-Ichi Ogawara
- 1 January 2023
- journal article
- research article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 80
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Doxil® — The first FDA-approved nano-drug: Lessons learnedJournal of Controlled Release, 2012
- Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effectsAdvanced Drug Delivery Reviews, 2011
- Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrinJournal of Controlled Release, 2009
- In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cellsJournal of Controlled Release, 2009
- Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in ratsInternational Journal of Pharmaceutics, 2008
- Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumorJournal of Controlled Release, 2005
- Non-ionic surfactant based vesicles (niosomes) in drug deliveryInternational Journal of Pharmaceutics, 1998
- Clinical Pharmacokinetics of DoxorubicinClinical Pharmacokinetics, 1988
- The Membrane Attack Complex of ComplementAnnual Review of Immunology, 1986
- The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in miceJournal of Pharmacy and Pharmacology, 1985